KRAS and non-small cell lung carcinoma: The exploratory analysis results of the above three clinical studies showed that for NSCLC patients with KRAS or KRAS G12C mutation, immunotherapy alone or combined chemotherapy ± antiangiogenic therapy can bring better clinical benefits to patients than chemotherapy ± antiangiogenic therapy.